Bone Morphogenetic Proteins Market Size, Share and Global Trend By Type (rhBMP-2, rhBMP-7, Others), By Application (Spinal Fusion, Trauma Surgery, Reconstructive Surgery, Maxillofacial & Dental), and Regional Forecast, 2024-2032

Bone Morphogenetic Proteins have been approved by the Food Drug Administration(FDA) for various applications such as oral surgeries and spinal fusions. Bone morphogenetic proteins are a naturally occurring protein in the human body which stimulates bone formation and mainly essential for bone healing. They play an important role in the development of the central nervous system.

There are many types of bone morphogenetic proteins discovered, but BMP 2, 4, 6, 7 and 9 play a major role in bone formation. INFUSE by Medtronic contains recombinant human bone morphogenetic protein that is capable of initiating bone growth in targeted areas of the spine. Increased demand for INFUSE, a bone morphogenetic protein by used surgeons is expected to impact the global bone morphogenetic proteins treatment market positively. Furthermore, increased research on bone morphogenetic proteins for different application is poised to surge the growth in the Global Bone Morphogenetic Proteins Market. 

Increase in a number of spinal fusion procedures, rising incidences of traumatic injuries, and increased R&D spending are expected to fuel the global bone morphogenetic proteins market in the forecast period. Also, advantages of bone morphogenetic proteins such as shorter hospital stays, faster recovery, minimally invasive surgeries are some of the factors driving the global bone morphogenetic proteins market. 

The risk associated with biocompatibility, high cost, and the presence of alternative products such as bone grafts, scaffolds, and others are the factors that can inhibit the growth of global bone morphogenetic proteins market. 

Key Players Covered 

Some of the major companies that are present in the global bone morphogenetic proteins market are Medtronic, Cellumed Co. Ltd, Sigma-Aldrich Co., Prospect- Tany Technogene Ltd., Ember Therapeutics, DePuy Synthes and others. 

 SEGMENTATION

At present, the rhBMP-2 protein is expected to hold the largest market share owing to its high usage by surgeons and physicians and the rise in a number of sports injuries. Spinal fusion segment is expected to grow exponentially during the forecast period owing to increased spinal injuries and rise in a number of spinal fusion surgeries. 

Key Insights 

• Number of spinal fusion surgery for key countries


• The regulatory scenario for key countries


• Reimbursement Scenario for key countries


• Pipeline Analysis


• Pricing Analysis


• New Product Launch


• Recent industry developments such as partnerships, mergers, and acquisitions  

Regional Analysis

North America is expected to dominate the global bone morphogenetic proteins market during the forecast years owing to the rapid adoption for Infuse bone morphogenetic protein, increased research on recombinant bone morphogenetic protein, and increased demand for bone growth stimulators. The bone morphogenetic proteins market in Europe anticipated expanding in the forecast period owing to the increasing prevalence of spinal injuries and an increase in a number of orthopedic surgeries. Asia Pacific is expected to register a remarkable growth during the forecast period, owing to a reasing number of standalone orthopedic clinics and growing awareness of advanced products and treatments.  

Key Industry Developments    

• In November 2018, STEMGEN S.p.A. updated the phase 1 results of hrBMP4. This is a study of human- recombinant bone morphogenetic protein 4 administrated via Convection-Enhanced Delivery (CED) in patients with Glioblastoma multiforme (GBM).
• In April 2018, Medtronic received expanded FDA approval for Infuse, a bone morphogenetic protein for a new indication of spinal surgery
• From January 2012- December 2018, University of Zagreb School of Medicine (UZSM) developed the novel therapy called OSTEOGROW which is composed of an autologous blood coagulum (ABC) gained from the patient’s blood and a biologically active ingredient recombinant human morphogenetic protein 6 (rhBMP6).